GlassScriptPhysician profile
William Daniel Chapman
NPI 1184129512
$52,618.47
in general payments reported to CMS, 2019-2025
12 companies · $41K in 2025
The $41K reported for 2025 was more than what 96% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $872 · 2024: $11K · 2025: $41K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $32K · Consulting Fee: $12K · Food and Beverage: $5,601 · Travel and Lodging: $2,313 · Education: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $32,382.50 |
| Consulting Fee | $12,021.94 |
| Food and Beverage | $5,600.59 |
| Travel and Lodging | $2,313.44 |
| Education | $300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $19,268.80 | 2023-2025 | Tysabri, Vumerity |
| Tg Therapeutics, INC. | $11,793.21 | 2023-2025 | |
| Amgen INC. | $7,257.09 | 2024-2025 | Uplizna |
| Abbvie INC. | $5,166.41 | 2024-2025 | |
| Emd Serono, INC. | $3,825.43 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $3,528.24 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $807.30 | 2023-2025 | Ultomiris, Soliris |
| E.R. Squibb & Sons, L.L.C. | $339.78 | 2023-2025 | Zeposia |
| Genzyme Corporation | $336.45 | 2023-2024 | |
| Genentech USA, INC. | $175.27 | 2024 | Ocrevus, Ocrevus Zunovo |
| Horizon Therapeutics Plc | $98.40 | 2023 | Uplizna |
| Vanda Pharmaceuticals INC. | $22.09 | 2025 | Ponvory |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Chapman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.